Hiding in Plain Sight: an Approach to Treating Patients with Severe COVID-19 Infection

mBio. 2020 Mar 20;11(2):e00398-20. doi: 10.1128/mBio.00398-20.

Abstract

Patients with COVID-19 infection are at risk of acute respiratory disease syndrome (ARDS) and death. The tissue receptor for COVID-19 is ACE2, and higher levels of ACE2 can protect against ARDS. Angiotensin receptor blockers and statins upregulate ACE2. Clinical trials are needed to determine whether this drug combination might be used to treat patients with severe COVID-19 infection.

Keywords: COVID-19; endothelial dysfunction; generic drugs; host response treatment.

MeSH terms

  • Angiotensin II Type 2 Receptor Blockers / therapeutic use
  • Angiotensin-Converting Enzyme 2
  • Betacoronavirus*
  • COVID-19
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / metabolism*
  • Coronavirus Infections / therapy*
  • Coronavirus Infections / virology
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Peptidyl-Dipeptidase A / metabolism
  • Pneumonia, Viral / metabolism*
  • Pneumonia, Viral / therapy*
  • Pneumonia, Viral / virology
  • Receptor, Angiotensin, Type 2 / biosynthesis*
  • Receptors, Coronavirus
  • Receptors, Virus / biosynthesis*
  • SARS-CoV-2

Substances

  • AGTR2 protein, human
  • Angiotensin II Type 2 Receptor Blockers
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Receptor, Angiotensin, Type 2
  • Receptors, Coronavirus
  • Receptors, Virus
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2

Supplementary concepts

  • COVID-19 drug treatment